NCT05970679View on ClinicalTrials.gov

Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A

PHASE3CompletedINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

August 17, 2022

Primary Completion Date

April 13, 2023

Study Completion Date

April 13, 2023

Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
DRUG

Ezetimibe/Atorvastatin 10/5 mg

DW1125

DRUG

Atorvastatin 5mg

DW1125A

DRUG

Ezetimibe 10mg

DW1125E

DRUG

Atorvastatin 10mg

DW1125A-1

DRUG

DW1125 placebo

Ezetimibe/Atorvastatin 10/5 mg placebo

DRUG

DW1125A placebo

Atorvastatin 5mg placebo

DRUG

DW1125E placebo

Ezetimibe 10mg placebo

DRUG

DW1125A-1 placebo

Atorvastatin 10mg placebo

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Daewon Pharmaceutical Co., Ltd.

INDUSTRY

NCT05970679 - Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A | Biotech Hunter | Biotech Hunter